Wolverine Stack: What BPC-157 and TB-500 Research Shows

The Wolverine stack is an informal name for pairing BPC-157 with TB-500. In a rat tendon study published July 23, 2026, researchers tested the peptides separately and together. The combination offered no additional benefit over either peptide alone in that experiment.

FDA has found different molecules sold as TB-500. That inconsistent naming complicates comparisons between experiments.

The study that tested the pair

Ozancan Biçer and colleagues assigned 32 male rats to four groups: controls, BPC-157, a material labeled TB-500, and the combination. At day 30, four tendons per group went to mechanical testing and four to tissue analysis.

Only the TB-500 group differed significantly from controls in the force required to break the tendon. The combination improved the Movin score, which grades tendon tissue changes, versus controls but did not outperform either peptide alone. The authors described the work as exploratory. Its small sample and single assessment point leave substantial room for further experiments. Read the study.

TB-500 needs an exact sequence

In its July 2026 briefing document, FDA describes TB-500 as a seven-amino-acid fragment of thymosin beta-4, with an acetyl group at one end. Its sequence is Ac-LKKTETQ. Full-length thymosin beta-4 contains 43 amino acids.

FDA also reported inconsistent naming across commercial materials, including different active molecules sold under the same common name. That creates a problem when selecting a reference standard for chemical testing.

For a BPC-157/TB-500 blend, the laboratory should record the exact identity of each component. A paper about full-length thymosin beta-4 answers a different experimental question from a paper about one of its fragments.

The sequence difference has experimental consequences. In a 2003 study of thymosin beta-4 and related fragments, researchers used synthetic peptides to investigate how particular regions affected blood-vessel formation. They traced activity to a specific seven-amino-acid region. Their approach depended on knowing precisely which sequence each experiment used.

What the individual peptide studies measured

BPC-157 contains 15 amino acids. A 2011 study of rat tendon fibroblasts found increased cell migration and greater outgrowth from tendon explants exposed to the peptide. The researchers also measured increased phosphorylation of FAK and paxillin, proteins associated with cell adhesion and movement.

Cell proliferation was not directly increased in that experiment. Migration and proliferation are separate measurements, even when both appear in discussions of tissue research.

The BPC-157 paper and the thymosin fragment experiments give researchers specific observations to investigate. Neither tested a Wolverine stack blend. Their findings should stay attached to the molecule and experimental model used in each paper.

Synergy takes a separate experiment

“Synergy” has a narrower meaning in combination research than it does in product descriptions. Researchers compare the observed response to a pair of compounds with the response predicted from the individual components under a stated reference model.

A larger response than either component alone can still be additive. The choice of reference model can also change the interpretation. The researchers behind SynergyFinder 3.0 describe methods for comparing models and reducing false-positive synergy findings.

For Wolverine stack research, a useful experiment measures both components separately alongside the pair under matched conditions. Repeated measurements help show whether an apparent difference persists. The analysis should name the model used to judge the interaction.

What to check on a blend’s COA

A certificate of analysis should identify the tested material clearly enough for another laboratory to follow the result back to the batch.

For a BPC-157/TB-500 blend, start with the component names and exact sequences. Check whether the report tested the finished blend or only the separate starting materials. Those are different samples.

Then look at what the laboratory actually measured. FDA’s TB-500 review examined a publicly available COA that included identity and peptide purity results but omitted other measurements, including assay and aggregates. A purity percentage can leave important questions about a sample unanswered.

Ask how much of each peptide the method measured and how the laboratory distinguished the components. A single headline percentage provides little detail about the amount of BPC-157 relative to TB-500 in the tested blend.

Keep the report with the matching lot number. NuLab’s guide to verifying a peptide COA explains how to check the laboratory record and confirm that the report belongs to the material being evaluated.

Wolverine stack research questions

Is the Wolverine stack a single peptide?

No. The term generally refers to BPC-157 paired with TB-500. A blend contains separate peptide components, each requiring its own identification.

Are TB-500 and thymosin beta-4 the same molecule?

Check the sequence: FDA’s review describes a seven-amino-acid fragment, while full-length thymosin beta-4 contains 43 amino acids.

Does a COA for each starting peptide cover the finished blend?

Those reports describe the starting samples. To evaluate the finished blend, look for a report tied to its own batch and tests that distinguish the components.

Source record

• Biçer and colleagues: BPC-157 and TB-500 in a rat tendon model, 2026.
• FDA: TB-500 chemistry and characterization briefing for the July 23–24, 2026 meeting.
• Philp and colleagues: The actin binding site on thymosin beta4 promotes angiogenesis, 2003.
• Chang and colleagues: BPC-157 in tendon explants and fibroblast experiments, 2011.
• Ianevski and colleagues: SynergyFinder 3.0, 2022.